US › Healthcare

CervoMed Inc. (CRVO)

US · Healthcare · Biotechnology

$2.55+4.51%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-6.6M

EPS

$-0.64

EPS estimate

$-0.87

EPS came in at -0.64 against a street estimate of -0.87 — a beat of 26.4%.

Key statistics

Market cap

$36.9M

Forward P/E

0.0

P/B

1.61

Book value

$1.70

EPS (TTM)

$-3.20

52-week high

$10.00

52-week low

$2.13

50-day MA

$2.76

200-day MA

$4.41

Beta

-4.31

Analyst view

Analysts rate CervoMed Inc. a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $15.40.

Shareholding

Insiders

26.43%

Institutions

22.29%

Largest institutional holders

Fund	Stake
Morgan Stanley - Brokerage Accounts	4.89%
Vanguard Capital Management, LLC	2.09%
Geode Capital Management, LLC	0.49%
Renaissance Technologies Corp	0.42%
BlackRock Inc	0.34%
Byrne Asset Management LLC	0.34%
XTX Topco Ltd	0.25%
Citizens Financial Group Inc	0.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CervoMed Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.